CRLCharles River Laboratories
Is the price fair?
Neither cheap nor expensive: nothing decisive, though rich vs its sector.
Priced for ~8% a year FCF growth. Moderate growth expectations are priced in.
In its normal range: P/E 24.8 vs a 28.5 median over 33 quarters (−13% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 27, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CRL's price assumes
Today's price asks for 8.1% free cash flow growth a year; over the last three years Charles River Laboratories delivered 8.6%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 4.2%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +8.1%
Growth the price implies · The price pays for +8.1% free cash flow growth a year for a decade; the business has delivered +8.6% a year over the last three.
- Price / book
- 3.14
Price / book · today's price, trailing year to Jun 27, 2026
Details›
- Price / booktoday's price, trailing year to Jun 27, 2026
- 3.14
- EV / EBIToperating margin 2.3%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 27, 2026
- 2.84
- Free cash flow, trailing twelve months
- $371M
- Market capitalisation
- $8.91B
- 3-year revenue growth
- −1.5%
- 3-year free cash flow growth
- +8.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry